BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36086966)

  • 21. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLAU, transcriptionally negatively regulated by GATA6, promotes lung squamous carcinoma cell proliferation and migration.
    Guo J; Wang H; Huang C; Lai C; Shang W; Luo S; Chen L
    Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119744. PubMed ID: 38702016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocadherin alpha 3 inhibits lung squamous cell carcinoma metastasis and epithelial-mesenchymal transition.
    Tao Y; Fei L; Chang L; Yongyu L; Jianhui J; Yanan L; Yi R
    Genes Genomics; 2022 Feb; 44(2):211-218. PubMed ID: 34086268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. lncRNA PSMA3-AS1 promotes the progression of non-small cell lung cancer through targeting miR-17-5p/PD-L1.
    Cheng G; Li Y; Liu Z; Song X
    Adv Clin Exp Med; 2021 Oct; 30(10):1043-1050. PubMed ID: 34610219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FUBP1 mediates the growth and metastasis through TGFβ/Smad signaling in pancreatic adenocarcinoma.
    Zhang Y; Chen J; Zhou N; Lu Y; Lu J; Xing X; Chen H; Zhang X
    Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33649780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-30a-5p hampers proliferation of lung squamous cell carcinoma through targeting FBXO45.
    Zeng F; You S; Dai X
    Histol Histopathol; 2022 May; 37(5):483-492. PubMed ID: 35098525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
    Gong L; Liu Q; Jia M; Sun X
    Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
    Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
    J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR.
    Xie A; Xu X; Kuang P; Zhang L; Yu F
    Cell Death Dis; 2021 Aug; 12(9):804. PubMed ID: 34429402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis.
    Zhang LX; Gao J; Long X; Zhang PF; Yang X; Zhu SQ; Pei X; Qiu BQ; Chen SW; Lu F; Lin K; Xu JJ; Wu YB
    Mol Cancer; 2022 May; 21(1):110. PubMed ID: 35525959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
    Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
    DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSMA1, a Poor Prognostic Factor, Promotes Tumor Growth in Lung Squamous Cell Carcinoma.
    Liu Z; Wang W; Zhou Y; Li L; Zhou W
    Dis Markers; 2023; 2023():5386635. PubMed ID: 36776923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
    Zhao F; Wang M; Zhu J
    Cancer Med; 2021 Sep; 10(17):6099-6113. PubMed ID: 34250747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
    Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
    Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
    Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas.
    Bao Z; Ji W; Yang Y; Chen Z; Li Z; Wang K; Lu T; Yu Y; Xia W; Lu S
    Exp Cell Res; 2020 Oct; 395(2):112187. PubMed ID: 32721391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of FUBP1 is associated with human cervical carcinoma development and prognosis.
    Ma C; Huang Z; Wu Z; Di C; Lin X; Huang M; Hong H; Yin H
    Life Sci; 2021 Mar; 269():119098. PubMed ID: 33476628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.